Findings

What do systematic reviews say?

27 questions · 27 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 3 · 11.1%Very low 0 · 0%Low 5 · 18.5%Moderate 7 · 25.9%High 12 · 44.4%

Intervention not reported

Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1024 participants
GRADE not reported

Intervention not reported

BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 498 participants
GRADE not reported

Intervention not reported

FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.72]
1 study · 32 participants
GRADE not reported

Intervention not reported

BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.01 [0.33, 3.1]
1 study · 96 participants
Low

Intervention not reported

BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.17 [0.57, 2.39]
1 study · 64 participants
Low

Intervention not reported

BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.27 [0.61, 2.66]
1 study · 58 participants
Low

Intervention not reported

BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.52 [0.69, 3.34]
2 studies · 83 participants
High